Primary Biliary Cholangitis

For chronic cholestatic liver tests, obtain PBC serology, particularly antimitochondrial antibody, and abdominal ultrasound to assess for biliary obstruction. The combination of cholestatic alkaline phosphatase and/or gamma-glutamyl transferase elevation with a PBC-specific autoantibody is sufficient for diagnosis in most patients and usually obviates biopsy. BMJ+1BMJPrimary biliary cholangitis - Symptoms, diagnosis and treatment | BMJ Best PracticeThe LancetPrimary biliary cholangitis

Do not infer disease severity from symptom burden. Pruritus and fatigue may substantially impair quality of life but do not correlate with disease stage. BMJ+1BMJPBC primary biliary cholangitis treatment and management ...BMJThe British Society of Gastroenterology/UK-PBC primary ...

When autoimmune hepatitis overlap is suspected, liver biopsy with expert clinicopathologic review is recommended by the BSG/UK-PBC guideline because true overlap appears uncommon and histology guides management. BMJBMJPBC primary biliary cholangitis treatment and management ...

PBC has heterogeneous progression: some patients progress slowly enough that disease may have limited clinical consequence, whereas others develop progressive biliary injury, fibrosis, cirrhosis, and end-stage liver disease. BMJ+1BMJPrimary biliary cholangitis - Symptoms, diagnosis and treatment | BMJ Best PracticeBMJThe British Society of Gastroenterology/UK-PBC primary ... Response to UDCA and longitudinal cholestatic biochemistry are central to risk stratification. BMJ+1BMJThe British Society of Gastroenterology/UK-PBC primary ...The Lancetdevelopment and validation of the UDCA Response Score

ALP normalization is an important treatment objective. Patients with an insufficient UDCA response, including those whose results remain in an historically acceptable range but are not normalized, have higher risk of liver transplantation or death than those with normalized ALP. BMJBMJChallenges facing the PBC community: insights from the PBC International Summit | Frontline Gastroenterology A Global PBC Study Group analysis cited a bilirubin threshold of 0.6 times the upper limit of normal as necessary to detect risk discrimination. The LancetThe LancetThe relationship between disease activity and UDCA ...

The BSG/UK-PBC guidance recommends annual serum liver tests and repeat documented risk assessment every 3 years. BMJBMJBritish Society of Gastroenterology/UK-PBC Primary Biliary ... In U.S. practice, monitoring frequency should also reflect treatment changes, biochemical activity, fibrosis stage, and decompensation risk.

UDCA is first-line therapy and slows disease progression. BMJBMJPrimary biliary cholangitis - Symptoms, diagnosis and treatment | BMJ Best Practice Contemporary treatment pathways use UDCA for a minimum of 12 months before formal biochemical response assessment. BMJBMJOptimising Primary thErapy in pRimAry biliary cholangitis ... The supplied evidence does not provide a source-supported U.S. dose; use current prescribing information and hepatology guidance when prescribing.

For adults with inadequate response to UDCA, elafibranor is FDA-approved in combination with UDCA; it is also approved as monotherapy when UDCA cannot be tolerated. Its 2024 approval is accelerated and based on ALP reduction; improvement in survival or prevention of liver decompensation has not been demonstrated. fdafdahighlights of prescribing information

Obeticholic acid improved ALP in the pivotal placebo-controlled trial and received accelerated approval based on biochemical improvement. fda+1fdaSerious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis | FDANEJMA Placebo-Controlled Trial of Obeticholic Acid in Primary ... However, FDA safety actions substantially constrain selection: it is contraindicated in advanced cirrhosis, including cirrhosis with current or prior decompensation or portal-hypertension features such as ascites, gastroesophageal varices, or persistent thrombocytopenia. fdafdaDue to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis | FDA FDA also reports serious liver injury in treated patients without cirrhosis, reinforcing the need for clinical and laboratory monitoring. fdafdaSerious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis | FDA

Pruritus, fatigue, sicca symptoms, abdominal discomfort, and arthralgias or bone pain are part of the PBC morbidity burden. BMJBMJThe British Society of Gastroenterology/UK-PBC primary ... Disease-modifying therapies and symptom-directed therapies should not be assumed to have the same effects: available review evidence notes that treatments modifying progression often do not improve symptoms, and symptom therapies do not substitute for biochemical disease control. BMJBMJPrimary biliary cholangitis - Symptoms, diagnosis and treatment | BMJ Best Practice

Linerixibat received FDA orphan-product listing approval for cholestatic pruritus associated with PBC in adults, with an approval date of March 17, 2026 in the supplied FDA listing. accessdata fdaaccessdata fdaSearch Orphan Drug Designations and Approvals Because the supplied source does not include prescribing information, dosing, contraindications, drug interactions, and monitoring parameters cannot be specified here; verify the current FDA label before use.

Use serial liver tests to establish trajectory after initiating or changing therapy. BSG/UK-PBC guidance recommends annual serum liver tests and documented repeat risk assessment every 3 years; more frequent evaluation is reasonable when biochemical activity persists, treatment is adjusted, or cirrhosis is present. BMJBMJBritish Society of Gastroenterology/UK-PBC Primary Biliary ...

For patients receiving obeticholic acid, FDA directs clinicians to monitor routinely for PBC progression using laboratory and clinical assessments and to assess for acute-on-chronic liver disease manifestations, including nausea, vomiting, diarrhea, jaundice, scleral icterus, or dark urine. Permanently discontinue for progression to advanced cirrhosis or development of these clinically significant liver-related adverse reactions. fdafdaDue to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis | FDA